Glenn G. Goddard
Net Worth
Last updated:
What is Glenn G. Goddard net worth?
The estimated net worth of Mr. Glenn G. Goddard is at least $10,901,287 as of 3 Jan 2024. He owns shares worth $415,996 as insider, has earned $8,235,491 from insider trading and has received compensation worth at least $2,249,800 in Intellia Therapeutics, Inc..
What is the salary of Glenn G. Goddard?
Mr. Glenn G. Goddard salary is $562,450 per year as Executive Vice President, Chief Financial Officer & Treasurer in Intellia Therapeutics, Inc..
How old is Glenn G. Goddard?
Mr. Glenn G. Goddard is 54 years old, born in 1971.
What stocks does Glenn G. Goddard currently own?
As insider, Mr. Glenn G. Goddard owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | Executive Vice President, Chief Financial Officer & Treasurer | 40,585 | $10.25 | $415,996 |
What does Intellia Therapeutics, Inc. do?
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Glenn G. Goddard insider trading
Intellia Therapeutics, Inc.
Mr. Glenn G. Goddard has made 7 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 5,365 units of NTLA stock worth $158,053 on 3 Jan 2024.
The largest trade he's ever made was exercising 24,800 units of NTLA stock on 31 Aug 2021. As of 3 Jan 2024 he still owns at least 40,585 units of NTLA stock.
Intellia Therapeutics key executives
Intellia Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. John M. Leonard (68) Pres, Chief Executive Officer & Director
- Dr. Laura Sepp-Lorenzino (64) Executive Vice President & Chief Scientific Officer
- Mr. Glenn G. Goddard (54) Executive Vice President, Chief Financial Officer & Treasurer